Pharma Q2FY26 Preview: Sector Faces Transition Quarter Amidst gRevlimid Declines and GST Impact
The pharma sector is expected to face a transition quarter in Q2FY26 due to declining gRevlimid sales, GST-related de-stocking, and a weak acute season in India. Revenue growth is projected between 7-10% YoY, while earnings may rise only 4-5%.